CN112574960B - 一种高效切割SARS-CoV-2基因组的siRNA及其应用 - Google Patents

一种高效切割SARS-CoV-2基因组的siRNA及其应用 Download PDF

Info

Publication number
CN112574960B
CN112574960B CN202011511680.5A CN202011511680A CN112574960B CN 112574960 B CN112574960 B CN 112574960B CN 202011511680 A CN202011511680 A CN 202011511680A CN 112574960 B CN112574960 B CN 112574960B
Authority
CN
China
Prior art keywords
artificial sequence
rna
dna
sirna
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011511680.5A
Other languages
English (en)
Other versions
CN112574960A (zh
Inventor
薛愿超
蔡兆奎
曹唱唱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Biophysics of CAS
Original Assignee
Institute of Biophysics of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Biophysics of CAS filed Critical Institute of Biophysics of CAS
Priority to CN202011511680.5A priority Critical patent/CN112574960B/zh
Publication of CN112574960A publication Critical patent/CN112574960A/zh
Application granted granted Critical
Publication of CN112574960B publication Critical patent/CN112574960B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供了一种高效切割SARS‑CoV‑2基因组的siRNA及其应用,涉及生物医药技术领域。本发明通过改进伴刀豆球蛋白A磁珠捕获病毒颗粒的技术,而后利用vRIC‑seq解析病毒颗粒中SARS‑CoV‑2的基因组RNA原位高级结构;再根据获得的病毒RNA结构,设计特异靶定病毒基因组RNA单链区的siRNA,开发的siRNA能够有效抑制SARS‑CoV‑2对Vero细胞的感染,提高受病毒感染的Vero细胞的存活率,并在细胞系中基本清除SARS‑CoV‑2 RNA,可以作为潜在的RNA药物用于COVID‑19的临床治疗。

Description

一种高效切割SARS-CoV-2基因组的siRNA及其应用
技术领域
本发明属于生物医药技术领域,具体涉及一种高效切割SARS-CoV-2基因组的siRNA及其应用。
背景技术
SARS-CoV-2(Severe acute respiratory syndrome coronavirus 2)是一种新发现的正链RNA病毒,隶属于冠状病毒科的β冠状病毒属。SARS-CoV-2病毒侵染人体后可引起呼吸道、消化道和神经系统疾病,严重情况下甚至会导致死亡。SARS-CoV-2病毒具有传播性且主要以人传人的方式传播。
siRNA以及RNA干扰是抑制病毒感染的一项重要技术,已在抑制HIV、HBV、HCV等病毒感染的相关研究中取得了重要进展。但是迄今,尚无基于SARS-CoV-2病毒基因组RNA结构设计高效siRNA以实现SARS-CoV-2病毒在细胞内清除的相关报道。
发明内容
有鉴于此,本发明的目的在于提供一种高效切割SARS-CoV-2基因组的siRNA及其应用,开发的siRNA能够有效抑制SARS-CoV-2对细胞的感染,提高受病毒感染细胞的存活率,并在细胞系中基本清除SARS-CoV-2RNA,可以作为潜在的RNA药物用于COVID-19的临床治疗。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种捕获SARS-CoV-2病毒颗粒的磁珠,所述磁珠包被伴刀豆球蛋白A。
本发明提供了上述磁珠在捕获SARS-CoV-2病毒颗粒中的应用。
本发明还提供了基于上述方法得到的SARS-CoV-2的原位结构所设计的靶向切割SARS-CoV-2基因组的siRNA,其特征在于,通过vRIC-seq解析所述SARS-CoV-2的RNA高级结构,选择位于单链区的RNA作为靶标,设计所述siRNA。
优选的,所述siRNA的正义链核苷酸序列如SEQ ID NO.1~SEQ ID NO.120所示,反义链序列如SEQ ID NO.121~SEQ ID NO.240所示。其中N代表A、G、C、T或U中的一种,除NN之外的核苷酸为siRNA主干序列。本发明实施例中,上述序列3’端“NN”为“TT”。
本发明还提供了基于上述siRNA所设计的与所述siRNA序列对应的小发夹RNA、引导RNA、反义寡核苷酸和锁核苷酸。
优选的,所述反义寡核苷酸的核苷酸序列为SEQ ID NO.121~SEQ ID NO.240所示序列中除3’端“NN”外的主干序列。
本发明还提供了一种抑制SARS-CoV-2感染的试剂,所述试剂包括上述siRNA或上述小发夹RNA、引导RNA、反义寡核苷酸和锁核苷酸。
优选的,所述抑制包括抑制SARS-CoV-2的拷贝和抑制所述SARS-CoV-2在细胞内的病毒丰度。
本发明还提供了上述siRNA或上述小发夹RNA、引导RNA、反义寡核苷酸和锁核苷酸或上述试剂在制备治疗SARS-CoV-2引发新型冠状病毒肺炎的药物中的应用。
本发明还提供了一种治疗SARS-CoV-2引发新型冠状病毒肺炎的药物,所述药物的有效成分包括上述siRNA或上述小发夹RNA、引导RNA、反义寡核苷酸和锁核苷酸或上述试剂。
本发明通过对伴刀豆球蛋白A(ConcanavalinA,ConA)磁珠捕获病毒颗粒的技术进行改进,而后利用病毒RNA原位构象测序技术(Virion RNA in situ conformationsequencing,简称vRIC-seq)解析病毒颗粒中SARS-CoV-2的基因组RNA原位高级结构;再根据获得的病毒RNA结构,设计特异靶定病毒基因组RNA单链区的siRNA,开发的siRNA能够有效抑制SARS-CoV-2对Vero细胞的感染,提高受病毒感染的Vero细胞的存活率,并在细胞系中基本清除SARS-CoV-2RNA,可以作为潜在的RNA药物用于COVID-19的临床治疗。在本发明实施例中,选取其中6条siRNA(SEQ ID NO.1~SEQ ID NO.6:siRNA-1、siRNA-2、siRNA-3、siRNA-4、siRNA-5和siRNA-6)进行功能验证,结果发现相对于对照组siRNA,siRNA-1、siRNA-2、siRNA-3、siRNA-4、siRNA-5和siRNA-6对病毒拷贝数的抑制率为别为82%、99%、96%、98%、99%和95%;且siRNA-1、siRNA-2、siRNA-3、siRNA-4、siRNA-5和siRNA-6对细胞中病毒丰度的抑制率为别为84%、99.6%、99.4%、99%、99.6%和64%。所以这些siRNA能够有效抑制SARS-CoV-2感染非洲绿猴肾(Vero)细胞,可用于开发针对SARS-CoV的RNA药物及临床治疗研究。
附图说明
图1为vRIC-seq技术概述及评估,其中a表示vRIC-seq技术流程;b表示比对到SARS-CoV-2基因组的嵌合体测序片段比例;c表示两个生物学重复之间的嵌合体测序片段数目(相互作用强度)的相关性散点图,R为皮尔逊相关系数;d表示嵌合体测序片段在SARS-CoV-2基因组上的分布Circos图,内部的红色圆圈表示100nt窗口内腺嘌呤或尿嘧啶的含量,外部的蓝色圆圈表示嵌合体测序片段的覆盖范围;e和f表示vRIC-seq捕获SARS-CoV-2RNA基因组的5'UTR(1~480nt,e)和3'UTR(29546~29870nt,f)中已知的冠状病毒保守性RNA结构;以不同颜色显示的连接分数用于评估碱基配对概率;虚线表征假结结构;
图2为SARS-CoV-2基因组三维高级构象,其中a表示相互作用的RNA片段所跨越的距离统计,标记的P1、P2和P3三个峰,分别对应于跨越810、1360和2090个核苷酸的相互作用片段;b表示SARS-CoV-2基因组RNA相互作用图谱,虚线三角形代表RNA拓扑结构域,黑线表征前导体(TRS-L)和基因(TRS-B)中的转录调节序列;c表示利用miniMDS软件模拟的SARS-CoV-2基因组RNA在病毒颗粒中的三维构象,vRIC-seq检测到的RNA相互作用频率用于构象模拟,红色实线表示支持局部相互作用的嵌合体信号,而红色虚线表示远距离相互作用;
图3为SARS-CoV-2基因组RNA二级结构,蓝色标记展示5'UTR,frame-shifting元件(frame-shifting element,FSE)和3'UTR中的已知结构元件;以不同的颜色显示成对的定量分析相互作用强度,黑色箭头突出显示由vRIC-seq检测到的高可信度远距离双链,绿色和紫色框分别标示起始和终止密码子,青色框勾勒出每个转录调控序列(transcription-regulatory sequence,TRS)的核心序列(core sequence,CS);
图4为基于结构设计siRNA抑制SARS-CoV-2感染Vero细胞,其中a表示siRNA抑制SARS-CoV-2感染Vero细胞的示意图;b表示用靶向单链区域(siRNA-1至siRNA-6)的siRNA转染后,上清液中的SARS-CoV-2拷贝降低至背景水平,其中Mock为未感染的细胞;si-NC为非靶向siRNA(阴性对照);c表示被感染Vero细胞中病毒RNA的相对丰度;b和c中的数据为平均值±s.e.m.;n=3个生物学重复,双尾t检验;d表示两条以上的siRNA组合可以切割目前流行的所有SARS-CoV-2突变株;
图5为单链特异性siRNA可高效抑制SARS-CoV-2,促进细胞存活;SARS-CoV-2感染后,用靶向单链区域的siRNA处理的Vero细胞的存活率要高于靶向双链区域的siRNA处理的细胞。
具体实施方式
本发明提供了一种捕获SARS-CoV-2病毒颗粒的磁珠,所述磁珠包被伴刀豆球蛋白A。在本发明中,所述SARS-CoV-2的包膜含有两种主要的糖蛋白:刺突蛋白和膜蛋白,而伴刀豆球蛋白A(ConA)可与糖蛋白特异性结合,有鉴于此,本发明首次使用包被ConA的磁珠捕获SARS-CoV-2病毒颗粒,以用于研究RNA病毒颗粒中基因组的原位高级结构。本发明所利用的磁珠优选购自Bangs Laboratories,Inc.公司,磁珠材质为Fe3O4,直径为1.0μm,浓度为5mg/mL。
本发明还提供了所述磁珠在捕获SARS-CoV-2病毒颗粒中的应用。在本发明中,利用所述磁珠捕获SARS-CoV-2病毒颗粒时,优选包括以下步骤:取出ConA磁珠,手动混匀;取1.5ml Eppendorf离心管,加入150μl磁珠,将离心管放置在磁力架上,待溶液澄清后,用移液枪吸去上清,加入500μl结合缓冲液(20mM HEPS-KOH pH 7.9,10mM KCl,1mM CaCl2,1mMMnCl2),用移液枪轻轻吹打混匀10次。将离心管放置在磁力架上,待溶液澄清后,弃上清。重复上述洗涤过程一次。向离心管中加入400μl结合缓冲液,100μl灭活病毒颗粒(溶剂为1×PBS),用移液枪上下吹打混匀10次。将离心管放在旋转混匀仪上,以20rpm室温旋转混匀10min。
本发明所述磁珠可特异性捕获病毒颗粒,以便于在磁珠上对病毒颗粒进行甲醛交联、核酶切割、pCp-biotin标记、原位近端连接和嵌合体RNA富集测序,从而完成vRIC-seq技术,对SARS-CoV-2的基因组原位高级结构进行解析,选择位于单链区的RNA作为靶标,设计siRNA。本发明对所述vRIC-seq技术的具体操作方案并没有特殊限定,优选与(ZhaokuiCai,Changchang Cao,Lei Ji,etc(2020).RIC-seq for global in situ profiling ofRNA–RNA spatial interactions.Nature,582,432~437)中的RIC-seq实验方案相同。
本发明还提供了基于上述方法得到的SARS-CoV-2的原位结构所设计的靶向切割SARS-CoV-2基因组的siRNA,通过vRIC-seq解析所述SARS-CoV-2的RNA高级结构,选择位于单链区的RNA作为靶标,设计所述siRNA。本发明所述siRNA的正义链核苷酸序列优选如SEQID NO.1~SEQ ID NO.120所示,反义链序列如SEQ ID NO.121~SEQ ID NO.240所示。本发明实施例中,上述序列3’端“NN”为“TT”。本发明对所述siRNA的设计原则并没有特殊限定,优选的根据SARS-CoV2二级结构,选取位于单链区的RNA片段作为靶标,基于文献(Lagana,A.,Shasha,D.,and Croce,C.M.(2014).Synthetic RNAs for Gene Regulation:DesignPrinciples and Computational Tools.Front Bioeng Biotechnol 2,65.)中的原则设计所述siRNA。
本发明还提供了基于上述siRNA所设计的与所述siRNA序列对应的小发夹RNA、引导RNA、反义寡核苷酸和锁核苷酸。本发明所述反义寡核苷酸的核苷酸序列优选为SEQ IDNO.121~SEQ ID NO.240所示序列中除3’端“NN”外的主干序列。
本发明还提供了一种抑制SARS-CoV-2感染的试剂,所述试剂包括上述siRNA或上述小发夹RNA、引导RNA、反义寡核苷酸和锁核苷酸。本发明所述抑制优选包括抑制SARS-CoV-2的拷贝和抑制所述SARS-CoV-2在细胞内的病毒丰度,如以商业siNC为阴性对照,(正义链序列SEQ ID NO.241:UUCUCCGAACGUGUCACGUTT;反义链序列SEQ ID NO.242:ACGUGACACGUUCGGAGAATT),对siRNA-1、siRNA-2、siRNA-3、siRNA-4、siRNA-5和siRNA-6进行实验,相对于对照组,siRNA-1、siRNA-2、siRNA-3、siRNA-4、siRNA-5和siRNA-6对病毒拷贝数的抑制率为别为82%、99%、96%、98%、99%和95%;且siRNA-1、siRNA-2、siRNA-3、siRNA-4、siRNA-5和siRNA-6对细胞中病毒丰度的抑制率为别为84%、99.6%、99.4%、99%、99.6%和64%,显然上述6条siRNA均表现出明显的SARS-CoV-2抑制作用。
本发明还提供了上述siRNA或上述小发夹RNA、引导RNA、反义寡核苷酸和锁核苷酸或上述试剂在制备治疗SARS-CoV-2感染的药物中的应用。
本发明所述SARS-CoV-2感染的宿主并没有特殊限定,可以是细胞系、组织、有机体等,如Vero细胞系以及其他细胞、组织、动物和人体。
本发明还提供了一种治疗SARS-CoV-2感染的药物,所述药物的有效成分包括上述siRNA或上述小发夹RNA、引导RNA、反义寡核苷酸和锁核苷酸或上述试剂。本发明对所述药物的剂型并没有特殊限定,优选包括注射给药剂型等。在本发明中,所述药物中有效成分的含量优选为20nM。
下面结合实施例对本发明提供的一种高效切割SARS-CoV-2基因组的siRNA及其应用进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
本实施例中所有与SARS-CoV-2活病毒有关的活体实验均在中华人民共和国国家卫生委员会授权的增强型生物安全3级(P3+)设施中进行。实施例中使用的SARS-CoV-2菌株IPBCAMS-YL01/2020是由中国医学科学院北京协和医学院病原生物学研究所从临床样本中分离出来的。使用前,该病毒在Vero细胞(ATCC,CCL-81)中传代了3次。通过斑块测定法在Vero细胞中测定SARS-CoV-2的感染滴度。根据已发表文献(Qiang Gao,Linlin Bao,HaiyanMao,etc(2020).Development ofan inactivated vaccine candidate for SARS-CoV-2.Science,369,77~81)对病毒进行了灭活及收集。
实施例1
vRIC-seq文库的制备、SARS-CoV-2结构解析、基于RNA结构设计siRNA及功能验证
根据已发表文献(Zhaokui Cai,Changchang Cao,Lei Ji,etc(2020).RIC-seqfor global in situ profiling of RNA–RNA spatial interactions.Nature,582,432~437)中的RIC-seq实验方案,根据图1所示流程构建SARS-CoV-2病毒颗粒的vRIC-seq文库。对测序数据进行分析后推断出SARS-CoV2的高级结构(图2)、二级结构(图3),根据此结构设计特异靶定SARS-CoV-2单链RNA区的siRNA,发现这些siRNA能够有效抑制SARS-CoV-2感染Vero细胞,可对目前流行各种SARS-CoV-2突变株基因组RNA进行切割。具体步骤如下:
1.取两个eppendorf 1.5-ml离心管,分别加入150μl ConcanavalinA磁珠,将离心管放在磁力架上,待溶液澄清后,用移液枪吸去上清,加入500μl结合溶液(20mM HEPS-KOHpH 7.9,10mM KCl,1mM CaCl2,1mM MnCl2),用枪轻轻吹打混匀10次,将离心管放在磁力架上,待溶液澄清后,用移液枪吸去上清。重复上述洗涤过程1次。加入400μl结合溶液、100μl灭活病毒颗粒,重悬ConcanavalinA磁珠。室温孵育10分钟。
2.将离心管放在磁力架上,待溶液澄清后,用移液枪吸去上清,磁珠用结合溶液洗四次,每次用量为600μl,用600μl PBST溶液(1×PBS,0.1%Tween 20)洗一次。
3.磁珠用1ml PBST溶液重悬,加入27μl 37%(质量/体积)甲醛,用移液枪上下吹打10次混匀。将离心管放在旋转混匀仪上,以20rpm室温旋转混匀10分钟。加入50μl 2.5M甘氨酸,用移液枪上下吹打10次混匀。将离心管放在旋转混匀仪上,以20rpm室温旋转混匀5分钟。
4.透化处理、微球菌核酸酶处理、pCp-biotin标记步骤参考已发表文献(ZhaokuiCai,Changchang Cao,Lei Ji,etc(2020).RIC-seq for global in situ profiling ofRNA–RNA spatial interactions.Nature,582,432~437),其中1×PNK溶液、1×PNK+EGTA溶液和Hight-salt溶液中的NP-40替换为0.1%(体积/体积)Tween 20。
5.近端连接前的FastAP处理与PNK处理合并为一步PNK处理,其中反应缓冲液为50mM imidazole-HCl pH 6.4、10mM MgCl2、10mM DTT。根据已发表文献(Cameron,V.,andUhlenbeck,O.C.(1977).3’-Phosphatase activity in T4 polynucleotidekinase.Biochemistry 16,5120-5126.),T4 PNK在上述缓冲液中同时具有较高的磷酸酶和激酶活性。
6.经RNA纯化和文库构建后,使用Illumina HiSeq X Ten测序仪对文库进行PE150双端测序。
7.根据已发表文献(Zhaokui Cai,Changchang Cao,Lei Ji,etc(2020).RIC-seqfor global in situ profiling of RNA–RNA spatial interactions.Nature,582,432~437)中的数据分析流程,对测序得到的原始数据进行前处理,随后利用分析流程(https://github.com/caochch/RIC2Structure)重构出SARS-CoV-2的二级结构(图3)和三级结构(图2)。
8.根据图1中b结果所示,97.3%的测序数据比对到SARS-CoV-2的基因组。表明ConA磁珠成功捕获SARS-CoV-2病毒颗粒。证明本发明中使用的ConA磁珠能够有效捕获病毒颗粒。
9.根据SARS-CoV2二级结构,选取位于单链区的RNA片段作为靶标,基于已发表文献(Lagana,A.,Shasha,D.,and Croce,C.M.(2014).Synthetic RNAs for GeneRegulation:Design Principles and Computational Tools.Front Bioeng Biotechnol2,65.)中的原则设计siRNA,一共设计了120条siRNA,siRNA正义链的核苷酸序列如SEQ IDNO.1~SEQ ID NO.120所示,反义链序列如SEQ ID NO.121~SEQ ID NO.240所示。
10.选取SEQ ID NO.1~6所示的六条siRNA(siRNA-1,siRNA-2,siRNA-3,siRNA-4,siRNA-5和siRNA-6),以商业siNC为阴性对照(正义链序列SEQ ID NO.241:UUCUCCGAACGUGUCACGUTT;反义链序列SEQ ID NO.242:ACGUGACACGUUCGGAGAATT)。siRNA正义链与反义链序列委托上海吉玛制药技术有限公司进行合成并退火成双链RNA。
11.siRNA转染Vero细胞:利用Invitrogen公司Lipofectamine RNAiMAX试剂将siRNA转染至24孔板内的Vero细胞(8×104cells/孔)。转染siRNA的细胞在生物安全等级3(P3+)实验室中感染SARS-CoV-2(MOI=0.05),细胞由Opti-MEM培养基在37℃培养1小时后,移除含有病毒的培养基并用新鲜Opti-MEM培养基洗一次,然后在维持培养基(OPTI-MEM培养基含有1%(质量/体积)BSA和1%(体积/体积)青霉素/链霉素)中培养24小时。
12.RNA样品提取:为了检测上清中病毒含量,收集100μl含有病毒的培养基上清,病毒RNA利用TRIzol LS试剂(公司为:Invitrogen,货号为:10296028)进行提取并经过Direct-zolTM RNA MiniPrep试剂盒(公司为:ZYMO RESEARCH,货号为:R2050)纯化。为了检测细胞中病毒RNA丰度,利用Trizol试剂(公司为:Invitrogen,货号为:15596026)提取感染SARS-CoV-2病毒的Vero细胞总RNA。
13.荧光定量PCR检测上清和细胞中病毒含量:为了检测上清中病毒含量,利用TaqMan Fast Virus 1-Step MasterMix(Thermo Fisher Scientific,货号为:4444432)进行TaqMan RT-PCR分析,实验操作按照试剂盒说明书。选择的靶标基因SARS-CoV-2N蛋白。
所用的探针及引物序列为,探针(FAM-SEQ ID NO.243-BHQ):5’-FAM/CAGCGCTTCAGCGTTCTTCGGAATGTCGC/3’-BHQ,上游引物(SEQ ID NO.244)为:5’-AACACAAGCTTTCGGCAGAC-3’,下游引物(SEQ ID NO.245)为:5’-ACCTGTGTAGGTCAACCACG-3’。
为了检测细胞中病毒含量,感染病毒细胞总RNA经RQ1 RNase-free DNase(Promega,货号为:M6101)处理后,由MMLV反转录酶(Promega,货号为:M1701)利用oligo dT(20)引物反转录成cDNA;利用HieffqPCR SYBR Green MasterMix(YEASEN,货号为:11203ES08)进行qPCR分析,选取的靶标基因为SARS-CoV2 RdRp,上游引物(SEQ ID NO.246)为:5’-CAAATTCTATGGTGGTTGGCACA-3’,下游引物(SEQ ID NO.247)为:5’-GGCATGGCTCTATCACATTTAGG-3’,选取的内参基因为Vero GAPDH,上游引物(SEQ ID NO.248)为:5’-GTCTCCTCTGACTTCAACAGCG-3’,下游引物(SEQ ID NO.249)为:5’-ACCACCCTGTTGCTGTAGCCAA-3’。所用TanMan探针委托上海生工生物工程公司合成,所用引物委托华大基因公司合成。
结果如图4~5和表1所示,其中Mock为空白对照,未感染的细胞;TaqMan RT-PCR分析结果表明,相对于对照组siRNA,siRNA-1、siRNA-2、siRNA-3、siRNA-4、siRNA-5和siRNA-6对病毒拷贝数的抑制率为别为82%、99%、96%、98%、99%和95%。RT-qPCR分析结果表明相对于对照组siRNA,siRNA-1、siRNA-2、siRNA-3、siRNA-4、siRNA-5和siRNA-6对细胞中病毒丰度的抑制率为别为84%、99.6%、99.4%、99%、99.6%和64%。用靶向单链区域的siRNA转染后,上清液中的SARS-CoV-2拷贝降低至背景水平;且两条以上的siRNA组合可以切割目前流行的所有SARS-CoV-2突变株;SARS-CoV-2感染后,用靶向单链区域的siRNA处理的Vero细胞的存活率要高于靶向双链区域的siRNA处理的细胞,因此单链特异性siRNA可高效抑制SARS-CoV-2,促进细胞存活。
表1 siRNA转染对SARS-CoV-2的影响
Figure GDA0002948653090000101
Figure GDA0002948653090000111
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 中国科学院生物物理研究所
<120> 一种高效切割SARS-CoV-2基因组的siRNA及其应用
<141> 2020-12-18
<160> 249
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 1
cacacgucca acucaguuun n 21
<210> 2
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 2
gccccuuuuc ucuaucuuun n 21
<210> 3
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 3
ccaccacaaa ccucuaucan n 21
<210> 4
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 4
ggagucaaau uacauuacan n 21
<210> 5
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 5
caccugaaga acauuuuaun n 21
<210> 6
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 6
gagcccuaau guguaaaaun n 21
<210> 7
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 7
gaaggcugau gaaacucaan n 21
<210> 8
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 8
caacuggacu uuauugacan n 21
<210> 9
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 9
caugagcaug aaauugcuun n 21
<210> 10
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 10
ccaaggguug aaaagaaaan n 21
<210> 11
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 11
ggguugaaaa gaaaaagcun n 21
<210> 12
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 12
guuacaaaag gaaaagcuan n 21
<210> 13
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 13
ggccgcuaua acaauacuan n 21
<210> 14
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 14
gggauuguac agaaagugun n 21
<210> 15
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 15
gccccaaaag aaauuaucun n 21
<210> 16
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 16
cuggugauuu acaaccauun n 21
<210> 17
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 17
caauaccuuc acacucaaan n 21
<210> 18
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 18
gguuacaaga gugugaauan n 21
<210> 19
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 19
guugaaucug augauuacan n 21
<210> 20
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 20
gacauucaac uucuuaagan n 21
<210> 21
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 21
guucuacuug caccauuaun n 21
<210> 22
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 22
gaucgcugag auuccuaaan n 21
<210> 23
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 23
guaaaccuuc aguugaacan n 21
<210> 24
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 24
cagagaaaac aagaugauan n 21
<210> 25
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 25
gaaaaucaaa gcuuguguun n 21
<210> 26
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 26
gcuuguguug aagaaguuan n 21
<210> 27
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 27
caacucugga agaaacuaan n 21
<210> 28
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 28
cucuggaaga aacuaaguun n 21
<210> 29
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 29
cuaaguuccu cacagaaaan n 21
<210> 30
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 30
gugccaacag acaauuauan n 21
<210> 31
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 31
gacagugcuu aaaaagugun n 21
<210> 32
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 32
caacuguagc gucacuuaun n 21
<210> 33
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 33
cacacuuaac gaucuaaaun n 21
<210> 34
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 34
cgaucuaaau gaaacucuun n 21
<210> 35
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 35
cacuccaaca aauagaguun n 21
<210> 36
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 36
cuuuugugca cuuaucuuan n 21
<210> 37
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 37
caaugaguua cuuguuucan n 21
<210> 38
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 38
gguccuauua cggauguuun n 21
<210> 39
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 39
caguuacaca acaaccauan n 21
<210> 40
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 40
ccauaaaacc aguuacuuan n 21
<210> 41
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 41
ccuauuguuu ggcauguuan n 21
<210> 42
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 42
cuaauaaagc cacguauaan n 21
<210> 43
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 43
gccacguaua aaccaaauan n 21
<210> 44
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 44
gccuuuucuu aacaaaguun n 21
<210> 45
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 45
cauaguuaca cgguguuuan n 21
<210> 46
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 46
ccguguuugu acuaauuaun n 21
<210> 47
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 47
gagugucggu aaauuuugun n 21
<210> 48
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 48
guguuugccu agguucuuun n 21
<210> 49
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 49
ggcuauuuga acucuacuan n 21
<210> 50
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 50
cucuacuaau gucacuauun n 21
<210> 51
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 51
ccuacuguac ugguucuaun n 21
<210> 52
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 52
cuuguaugau guguuacaan n 21
<210> 53
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 53
gaaugugucc uuagacaaun n 21
<210> 54
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 54
guuacuggcg auaguuguan n 21
<210> 55
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 55
gucacaacau ugcuuugaun n 21
<210> 56
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 56
cuacgaaaac aaauacguan n 21
<210> 57
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 57
cuacuagaca aguuguuaan n 21
<210> 58
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 58
caacaaagau agcacuuaan n 21
<210> 59
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 59
guuacacuug uguuccuuun n 21
<210> 60
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 60
gugaaaucau aggauacaan n 21
<210> 61
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 61
gccaguacca uauuguuaun n 21
<210> 62
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 62
caccaguuua cucauucuun n 21
<210> 63
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 63
gcauuucuau ugguucuuun n 21
<210> 64
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 64
gagacgugua gucuuuaaun n 21
<210> 65
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 65
cucagaguag aaucaucaun n 21
<210> 66
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 66
gcuaugaccc aaauguauan n 21
<210> 67
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 67
cagcagccaa acuaauggun n 21
<210> 68
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 68
gggagguagg uuuguacuun n 21
<210> 69
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 69
cugguacuau cuauacagan n 21
<210> 70
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 70
ccaccuugua gguuuguuan n 21
<210> 71
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 71
ccuaaauaga gguaugguan n 21
<210> 72
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 72
ccaaucacua auuguguuan n 21
<210> 73
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 73
gccaauaugg aucaagaaun n 21
<210> 74
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 74
gguaauugug acacauuaan n 21
<210> 75
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 75
cugcagaguc acauguugan n 21
<210> 76
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 76
cuuacauagc ucuagacuun n 21
<210> 77
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 77
caaagacuuc uaugacuuun n 21
<210> 78
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 78
ggaaguucug uugaauuaan n 21
<210> 79
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 79
gaugcacuuu ucgcauauan n 21
<210> 80
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 80
cuguuuauag ugauguagan n 21
<210> 81
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 81
cugcuuaugc uaauagugun n 21
<210> 82
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 82
cgguucgugu cuuuagcuan n 21
<210> 83
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 83
ccacccauua guuuuccaun n 21
<210> 84
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 84
gagcacuaug uuagaauuan n 21
<210> 85
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 85
gugacacacu uaaaaaucun n 21
<210> 86
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 86
ccaugaucug uauugucaan n 21
<210> 87
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 87
gcguguugac uggacuauun n 21
<210> 88
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 88
ccucuggaac acuuuuacan n 21
<210> 89
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 89
cacuguuuac acaaaaguun n 21
<210> 90
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 90
gagaugcucc agcacauaun n 21
<210> 91
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 91
cccaggaguc aaauggaaan n 21
<210> 92
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 92
gauggccaug uagaaacaun n 21
<210> 93
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 93
cauuaccuaa aggcauaaun n 21
<210> 94
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 94
cccuguccua ccauuuaaun n 21
<210> 95
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 95
cgcuacuaau guuguuauun n 21
<210> 96
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 96
ggaaaacagg guaauuucan n 21
<210> 97
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 97
ggaaucuauc aaacuucuan n 21
<210> 98
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 98
ccaacagaau cuauuguuan n 21
<210> 99
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 99
ccagguugcu guucuuuaun n 21
<210> 100
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 100
cacgugcagg cuguuuaaun n 21
<210> 101
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 101
cacccaagaa guuuuugcan n 21
<210> 102
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 102
caccaccaau uaaagauuun n 21
<210> 103
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 103
cacgcuuguu aaacaacuun n 21
<210> 104
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 104
ccugaauuag acucauucan n 21
<210> 105
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 105
cgaacuuaug gauuuguuun n 21
<210> 106
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 106
cuuugaagca aggugaaaun n 21
<210> 107
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 107
ggaugcuacu ccuucagaun n 21
<210> 108
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 108
cuugcuguug uuguuuguan n 21
<210> 109
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 109
gaacaugucc aaauucacan n 21
<210> 110
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 110
gcugaugagu acgaacuuan n 21
<210> 111
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 111
ccuucuuuuu acguuuacun n 21
<210> 112
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 112
ccaauggaga uugauuaaan n 21
<210> 113
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 113
gaacuuuacu cuccaauuun n 21
<210> 114
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 114
cuugucacgc cuaaacgaan n 21
<210> 115
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 115
cgaacaaacu aaaaugucun n 21
<210> 116
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 116
cuuccucaag gaacaacaun n 21
<210> 117
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 117
caguucaaga aauucaacun n 21
<210> 118
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 118
ggccaaacug ucacuaagan n 21
<210> 119
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 119
ggaacugauu acaaacauun n 21
<210> 120
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 120
gcauauugac gcauacaaan n 21
<210> 121
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 121
aaacugaguu ggacgugugn n 21
<210> 122
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 122
aaagauagag aaaaggggcn n 21
<210> 123
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 123
ugauagaggu uugugguggn n 21
<210> 124
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 124
uguaauguaa uuugacuccn n 21
<210> 125
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 125
auaaaauguu cuucaggugn n 21
<210> 126
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 126
auuuuacaca uuagggcucn n 21
<210> 127
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 127
uugaguuuca ucagccuucn n 21
<210> 128
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 128
ugucaauaaa guccaguugn n 21
<210> 129
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 129
aagcaauuuc augcucaugn n 21
<210> 130
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 130
uuuucuuuuc aacccuuggn n 21
<210> 131
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 131
agcuuuuucu uuucaacccn n 21
<210> 132
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 132
uagcuuuucc uuuuguaacn n 21
<210> 133
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 133
uaguauuguu auagcggccn n 21
<210> 134
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 134
acacuuucug uacaaucccn n 21
<210> 135
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 135
agauaauuuc uuuuggggcn n 21
<210> 136
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 136
aaugguugua aaucaccagn n 21
<210> 137
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 137
uuugagugug aagguauugn n 21
<210> 138
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 138
uauucacacu cuuguaaccn n 21
<210> 139
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 139
uguaaucauc agauucaacn n 21
<210> 140
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 140
ucuuaagaag uugaaugucn n 21
<210> 141
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 141
auaauggugc aaguagaacn n 21
<210> 142
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 142
uuuaggaauc ucagcgaucn n 21
<210> 143
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 143
uguucaacug aagguuuacn n 21
<210> 144
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 144
uaucaucuug uuuucucugn n 21
<210> 145
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 145
aacacaagcu uugauuuucn n 21
<210> 146
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 146
uaacuucuuc aacacaagcn n 21
<210> 147
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 147
uuaguuucuu ccagaguugn n 21
<210> 148
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 148
aacuuaguuu cuuccagagn n 21
<210> 149
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 149
uuuucuguga ggaacuuagn n 21
<210> 150
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 150
uauaauuguc uguuggcacn n 21
<210> 151
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 151
acacuuuuua agcacugucn n 21
<210> 152
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 152
auaagugacg cuacaguugn n 21
<210> 153
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 153
auuuagaucg uuaagugugn n 21
<210> 154
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 154
aagaguuuca uuuagaucgn n 21
<210> 155
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 155
aacucuauuu guuggagugn n 21
<210> 156
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 156
uaagauaagu gcacaaaagn n 21
<210> 157
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 157
ugaaacaagu aacucauugn n 21
<210> 158
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 158
aaacauccgu aauaggaccn n 21
<210> 159
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 159
uaugguuguu guguaacugn n 21
<210> 160
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 160
uaaguaacug guuuuauggn n 21
<210> 161
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 161
uaacaugcca aacaauaggn n 21
<210> 162
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 162
uuauacgugg cuuuauuagn n 21
<210> 163
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 163
uauuugguuu auacguggcn n 21
<210> 164
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 164
aacuuuguua agaaaaggcn n 21
<210> 165
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 165
uaaacaccgu guaacuaugn n 21
<210> 166
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 166
auaauuagua caaacacggn n 21
<210> 167
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 167
acaaaauuua ccgacacucn n 21
<210> 168
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 168
aaagaaccua ggcaaacacn n 21
<210> 169
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 169
uaguagaguu caaauagccn n 21
<210> 170
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 170
aauagugaca uuaguagagn n 21
<210> 171
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 171
auagaaccag uacaguaggn n 21
<210> 172
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 172
uuguaacaca ucauacaagn n 21
<210> 173
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 173
auugucuaag gacacauucn n 21
<210> 174
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 174
uacaacuauc gccaguaacn n 21
<210> 175
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 175
aucaaagcaa uguugugacn n 21
<210> 176
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 176
uacguauuug uuuucguagn n 21
<210> 177
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 177
uuaacaacuu gucuaguagn n 21
<210> 178
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 178
uuaagugcua ucuuuguugn n 21
<210> 179
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 179
aaaggaacac aaguguaacn n 21
<210> 180
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 180
uuguauccua ugauuucacn n 21
<210> 181
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 181
auaacaauau gguacuggcn n 21
<210> 182
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 182
aagaaugagu aaacuggugn n 21
<210> 183
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 183
aaagaaccaa uagaaaugcn n 21
<210> 184
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 184
auuaaagacu acacgucucn n 21
<210> 185
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 185
augaugauuc uacucugagn n 21
<210> 186
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 186
uauacauuug ggucauagcn n 21
<210> 187
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 187
accauuaguu uggcugcugn n 21
<210> 188
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 188
aaguacaaac cuaccucccn n 21
<210> 189
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 189
ucuguauaga uaguaccagn n 21
<210> 190
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 190
uaacaaaccu acaagguggn n 21
<210> 191
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 191
uaccauaccu cuauuuaggn n 21
<210> 192
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 192
uaacacaauu agugauuggn n 21
<210> 193
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 193
auucuugauc cauauuggcn n 21
<210> 194
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 194
uuaauguguc acaauuaccn n 21
<210> 195
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 195
ucaacaugug acucugcagn n 21
<210> 196
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 196
aagucuagag cuauguaagn n 21
<210> 197
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 197
aaagucauag aagucuuugn n 21
<210> 198
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 198
uuaauucaac agaacuuccn n 21
<210> 199
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 199
uauaugcgaa aagugcaucn n 21
<210> 200
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 200
ucuacaucac uauaaacagn n 21
<210> 201
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 201
acacuauuag cauaagcagn n 21
<210> 202
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 202
uagcuaaaga cacgaaccgn n 21
<210> 203
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 203
auggaaaacu aauggguggn n 21
<210> 204
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 204
uaauucuaac auagugcucn n 21
<210> 205
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 205
agauuuuuaa gugugucacn n 21
<210> 206
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 206
uugacaauac agaucauggn n 21
<210> 207
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 207
aauaguccag ucaacacgcn n 21
<210> 208
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 208
uguaaaagug uuccagaggn n 21
<210> 209
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 209
aacuuuugug uaaacagugn n 21
<210> 210
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 210
auaugugcug gagcaucucn n 21
<210> 211
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 211
uuuccauuug acuccugggn n 21
<210> 212
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 212
auguuucuac auggccaucn n 21
<210> 213
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 213
auuaugccuu uagguaaugn n 21
<210> 214
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 214
auuaaauggu aggacagggn n 21
<210> 215
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 215
aauaacaaca uuaguagcgn n 21
<210> 216
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 216
ugaaauuacc cuguuuuccn n 21
<210> 217
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 217
uagaaguuug auagauuccn n 21
<210> 218
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 218
uaacaauaga uucuguuggn n 21
<210> 219
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 219
auaaagaaca gcaaccuggn n 21
<210> 220
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 220
auuaaacagc cugcacgugn n 21
<210> 221
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 221
ugcaaaaacu ucuugggugn n 21
<210> 222
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 222
aaaucuuuaa uugguggugn n 21
<210> 223
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 223
aaguuguuua acaagcgugn n 21
<210> 224
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 224
ugaaugaguc uaauucaggn n 21
<210> 225
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 225
aaacaaaucc auaaguucgn n 21
<210> 226
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 226
auuucaccuu gcuucaaagn n 21
<210> 227
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 227
aucugaagga guagcauccn n 21
<210> 228
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 228
uacaaacaac aacagcaagn n 21
<210> 229
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 229
ugugaauuug gacauguucn n 21
<210> 230
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 230
uaaguucgua cucaucagcn n 21
<210> 231
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 231
aguaaacgua aaaagaaggn n 21
<210> 232
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 232
uuuaaucaau cuccauuggn n 21
<210> 233
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 233
aaauuggaga guaaaguucn n 21
<210> 234
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 234
uucguuuagg cgugacaagn n 21
<210> 235
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 235
agacauuuua guuuguucgn n 21
<210> 236
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 236
auguuguucc uugaggaagn n 21
<210> 237
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 237
aguugaauuu cuugaacugn n 21
<210> 238
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 238
ucuuagugac aguuuggccn n 21
<210> 239
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 239
aauguuugua aucaguuccn n 21
<210> 240
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 240
uuuguaugcg ucaauaugcn n 21
<210> 241
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 241
uucuccgaac gugucacgun n 21
<210> 242
<211> 21
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 242
acgugacacg uucggagaan n 21
<210> 243
<211> 29
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 243
cagcgcttca gcgttcttcg gaatgtcgc 29
<210> 244
<211> 20
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 244
aacacaagct ttcggcagac 20
<210> 245
<211> 20
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 245
acctgtgtag gtcaaccacg 20
<210> 246
<211> 23
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 246
caaattctat ggtggttggc aca 23
<210> 247
<211> 23
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 247
ggcatggctc tatcacattt agg 23
<210> 248
<211> 22
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 248
gtctcctctg acttcaacag cg 22
<210> 249
<211> 22
<212> DNA/RNA
<213> 人工序列(artificial sequence)
<400> 249
accaccctgt tgctgtagcc aa 22

Claims (3)

1.一种抑制SARS-CoV-2感染的试剂,其特征在于,所述试剂包括基于SARS-CoV-2的原位结构所设计的靶向切割SARS-CoV-2基因组的siRNA或基于所述siRNA所设计的与所述siRNA序列对应的小发夹RNA、引导RNA、反义寡核苷酸和锁核苷酸;
通过vRIC-seq解析所述SARS-CoV-2的RNA高级结构,选择位于单链区的RNA作为靶标,设计所述siRNA;所述siRNA的正义链核苷酸序列如SEQ ID NO:1~SEQ ID NO:6所示,所述siRNA的反义链核苷酸序列如SEQ ID NO:121~SEQ ID NO.126所示;
所述抑制包括抑制所述SARS-CoV-2的拷贝和抑制所述SARS-CoV-2在细胞内的病毒丰度。
2.权利要求1所述试剂在制备治疗SARS-CoV-2引发新型冠状病毒肺炎的药物中的应用。
3.一种治疗SARS-CoV-2引发新型冠状病毒肺炎的药物,其特征在于,所述药物的有效成分包括权利要求1所述试剂。
CN202011511680.5A 2020-12-18 2020-12-18 一种高效切割SARS-CoV-2基因组的siRNA及其应用 Active CN112574960B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011511680.5A CN112574960B (zh) 2020-12-18 2020-12-18 一种高效切割SARS-CoV-2基因组的siRNA及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011511680.5A CN112574960B (zh) 2020-12-18 2020-12-18 一种高效切割SARS-CoV-2基因组的siRNA及其应用

Publications (2)

Publication Number Publication Date
CN112574960A CN112574960A (zh) 2021-03-30
CN112574960B true CN112574960B (zh) 2022-09-23

Family

ID=75136250

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011511680.5A Active CN112574960B (zh) 2020-12-18 2020-12-18 一种高效切割SARS-CoV-2基因组的siRNA及其应用

Country Status (1)

Country Link
CN (1) CN112574960B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113262294B (zh) * 2021-05-31 2022-03-22 中国食品药品检定研究院 一种用于治疗冠状病毒感染的植物凝集素succ-Con A及应用
WO2022256409A2 (en) * 2021-06-02 2022-12-08 The Regents Of The University Of California Compositions and methods of modulating rna and protein interactions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112080585B (zh) * 2020-08-11 2023-11-07 上海市公共卫生临床中心 一种新型冠状病毒(SARS-CoV-2)快速检测试剂盒及其方法

Also Published As

Publication number Publication date
CN112574960A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
CN111748557B (zh) 抑制新型冠状病毒的小干扰核酸及组合物和应用
Jurak et al. Numerous conserved and divergent microRNAs expressed by herpes simplex viruses 1 and 2
CN112574960B (zh) 一种高效切割SARS-CoV-2基因组的siRNA及其应用
CN111494416B (zh) NK细胞外泌体及相关miRNA在制备COVID-19病毒抑制剂中的应用
CN117413063A (zh) 冠状病毒治疗性干扰颗粒
Shi et al. Novel microRNA‐like viral small regulatory RNAs arising during human hepatitis A virus infection
US20240102015A1 (en) Antisense Oligonucleotides Targeting SARS-CoV-2
CN111808858B (zh) 一种siRNA序列及其靶标在提高PEDV毒价中的应用
CN111057747B (zh) 具有去除宿主基因组dna功能的微生物核酸提取方法以及试剂盒
CN112266912A (zh) 靶向miR-29b的gRNA、AAV8-CRISPR/Cas9系统及其应用
Xu et al. Foot-and-mouth disease virus degrades Rab27a to suppress the exosome-mediated antiviral immune response
EP3081645B1 (en) Non-coding rna of in-vivo infected microorganisms, parasitic microorganisms, symbiotic microorganisms and identification and application thereof
EP3081647B1 (en) Avian influenza virus mirna, and appraisal, detection, and application thereof
JP2021522178A (ja) 病態治療のためのRNAエディターのmRNA駆動型発現
CN114364799B (zh) 编辑造血干/祖细胞中bcl11a基因的方法
WO2005019410A2 (en) Rnai agents for anti-sars coronavirus therapy
Wu et al. CRISPR/Cas9-Mediated Knockout of the Dicer and Ago2 Genes in BHK-21 Cell Promoted Seneca Virus A Replication and Enhanced Autophagy
US8895524B2 (en) Viral microRNA
Shah et al. The dual actions of the host miRNA-16a in restricting Bovine coronavirus (BCoV) replication through targeting host cell Furin and in enhancing the host immune response.
Tang et al. miR-342-5p targets CTNNBIP1 to promote enterovirus 71 replication
Baldassarre et al. Non-Coding RNAs and Innovative Therapeutic Strategies to Target the 5’UTR of SARS-CoV-2
US20220127602A1 (en) Grna targeting mir-29b, aav8-crisper/cas9 system and use thereof
Teng et al. Viral miRNA delivered by exosomes from Marek’s disease virus-transformed lymphoma cell line exerts regulatory function in internalized primary chicken embryo fibroblast cells
Tandon Future Advancement: Potential of Gene editing and RNAi in SARS-Cov-2 diagnosis and therapy
Cai et al. Protocol for profiling virus-to-host RNA-RNA interactions in infected cells by RIC-seq

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant